The Effect of Rosuvastatin on Adenosine Metabolism
Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adenosine Metabolism
Intervention: placebo (Drug); rosuvastatin (Drug)
Phase: N/A
Status: Completed
Sponsored by: Radboud University Official(s) and/or principal investigator(s): Gerard Rongen, MD, PhD, Study Director, Affiliation: Radboud University Medical Centre Dep. Pharmacology-Toxicology
Summary
The aim of this study is to show whether rosuvastatin influences adenosine metabolism.
Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation
by increased adenosine receptor stimulation.
Clinical Details
Official title: Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: forearm vasodilatory response to dipyridamole
Secondary outcome: lipid profile
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- age 18 - 50 years
- Signed informed consent
Exclusion Criteria:
- hypertension
- hypercholesterolemia
- diabetes Mellitus
- alanine aminotransferase > 90 U/L
- creatinine Kinase > 440 U/L
- cardiovascular disease
- GFR < 80 ml/min
Locations and Contacts
Radboud University Nijmegen Medical Centre, Nijmegen 6500 HB, Netherlands
Additional Information
Starting date: November 2007
Last updated: September 22, 2008
|